Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2015 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
AXSM on Nasdaq
Shares outstanding
48,932,355
Price per share
$182.64
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
37,163,707
Total reported value
$4,512,702,432
% of total 13F portfolios
0.01%
Share change
-703,541
Value change
-$68,301,522
Number of holders
350
Price from insider filings
$182.64
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RTW INVESTMENTS, LP 3.1% -48% $165,312,089 -$153,206,917 1,516,903 -48% RTW Investments, LP 30 Jun 2025

As of 30 Sep 2025, 350 institutional investors reported holding 37,163,707 shares of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM). This represents 76% of the company’s total 48,932,355 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) together control 50% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 8.5% 4,180,646 +6% 0.01% $507,739,457
BlackRock, Inc. 7.7% 3,790,929 -1.1% 0.01% $460,408,328
WELLINGTON MANAGEMENT GROUP LLP 2.7% 1,334,560 +84% 0.03% $162,082,313
RTW INVESTMENTS, LP 2.3% 1,118,883 -26% 1.7% $135,888,340
MACQUARIE GROUP LTD 2.2% 1,084,536 -4.7% 0.15% $131,717,000
PRICE T ROWE ASSOCIATES INC /MD/ 2.1% 1,037,448 +69% 0.01% $125,999,000
GEODE CAPITAL MANAGEMENT, LLC 2% 997,700 +0.83% 0.01% $121,188,899
Invesco Ltd. 2% 990,557 +73% 0.02% $120,303,148
STATE STREET CORP 1.9% 942,960 -1.6% 0% $114,522,492
FMR LLC 1.9% 927,883 -5% 0.01% $112,691,333
Deep Track Capital, LP 1.8% 900,000 +12% 3.1% $109,305,000
Fairmount Funds Management LLC 1.7% 815,176 0% 8.9% $99,003,125
EVENTIDE ASSET MANAGEMENT, LLC 1.5% 746,398 +2.9% 1.5% $90,637,842
ALETHEA CAPITAL MANAGEMENT, LLC 1.4% 670,883 +0.53% 52% $81,478,740
ORBIMED ADVISORS LLC 1.1% 531,800 +24% 1.5% $64,587,110
PFM Health Sciences, LP 1.1% 530,332 +9.8% 5.5% $64,408,821
BVF INC/IL 0.99% 486,757 -71% 2.4% $59,116,638
ADAGE CAPITAL PARTNERS GP, L.L.C. 0.91% 445,000 -0.45% 0.09% $54,045,250
MORGAN STANLEY 0.84% 409,580 -8.6% 0% $49,743,576
NORTHERN TRUST CORP 0.84% 409,535 +0.03% 0.01% $49,738,025
Sofinnova Investments, Inc. 0.8% 393,499 +320% 2.9% $47,790,454
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.78% 382,047 +7.1% 0.01% $46,399,608
MARSHALL WACE, LLP 0.77% 378,024 +567% 0.05% $45,911,016
PRINCIPAL FINANCIAL GROUP INC 0.75% 368,434 +3.6% 0.02% $44,746,308
Pictet Asset Management Holding SA 0.74% 362,138 -12% 0.04% $43,981,660

Institutional Holders of Axsome Therapeutics, Inc. - Common Stock, $0.0001 par value per share (AXSM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 780,997 $142,406,885 +$35,732,294 $182.64 30
2025 Q3 37,163,707 $4,512,702,432 -$68,301,522 $121.45 350
2025 Q2 37,843,872 $3,950,044,159 +$74,087,650 $104.39 345
2025 Q1 36,999,749 $4,315,367,902 +$55,229,563 $116.63 349
2024 Q4 37,175,235 $3,145,106,906 -$176,513,164 $84.61 290
2024 Q3 38,678,079 $3,475,093,026 -$190,434,872 $89.87 277
2024 Q2 40,712,369 $3,277,256,100 +$165,407,783 $80.50 253
2024 Q1 38,735,398 $3,089,970,732 +$16,979,676 $79.80 254
2023 Q4 38,597,370 $3,071,777,083 +$30,855,225 $79.59 242
2023 Q3 37,879,928 $2,647,367,402 +$88,702,381 $69.89 224
2023 Q2 36,371,724 $2,613,474,662 +$329,094,500 $71.86 227
2023 Q1 31,901,760 $1,967,140,427 +$94,141,631 $61.68 194
2022 Q4 30,053,540 $2,317,913,385 +$384,566,478 $77.13 213
2022 Q3 25,705,114 $1,146,849,855 +$196,048,585 $44.62 180
2022 Q2 21,590,557 $826,608,565 +$90,967,881 $38.30 164
2022 Q1 19,105,701 $787,305,601 +$28,307,048 $41.39 165
2021 Q4 18,632,401 $703,886,639 -$18,569,388 $37.78 161
2021 Q3 19,030,753 $625,717,799 -$187,658,523 $32.96 165
2021 Q2 22,332,926 $1,506,651,537 -$37,805,529 $67.46 172
2021 Q1 22,937,308 $1,299,681,826 -$60,738,349 $56.62 181
2020 Q4 23,974,672 $1,951,921,924 -$4,134,242 $81.47 178
2020 Q3 24,031,769 $1,711,934,785 -$21,143,954 $71.25 171
2020 Q2 24,239,746 $1,992,911,051 +$152,460,166 $82.28 188
2020 Q1 22,843,303 $1,344,655,517 +$45,174,721 $58.83 163
2019 Q4 22,285,098 $2,303,381,131 +$375,930,983 $103.36 168
2019 Q3 18,829,417 $381,131,444 +$8,748,444 $20.24 109
2019 Q2 18,265,403 $470,328,087 +$100,449,906 $25.75 107
2019 Q1 14,726,528 $209,555,043 +$159,660,613 $14.23 64
2018 Q4 3,826,666 $10,790,008 +$478,855 $2.82 35
2018 Q3 3,533,711 $12,193,010 -$1,993,489 $3.45 33
2018 Q2 4,098,087 $13,112,972 -$296,661 $3.20 34
2018 Q1 4,234,235 $10,372,895 -$6,125,369 $2.45 35
2017 Q4 5,822,045 $32,606,017 -$1,045,996 $5.60 33
2017 Q3 6,009,091 $33,278,940 -$2,137,110 $5.55 26
2017 Q2 6,403,943 $35,253,289 -$6,146,767 $5.50 34
2017 Q1 7,754,027 $30,238,589 +$7,294,468 $3.90 47
2016 Q4 6,167,172 $41,627,505 -$969,516 $6.75 41
2016 Q3 6,308,290 $49,689,460 +$4,018,404 $7.88 36
2016 Q2 5,799,374 $43,724,574 +$3,925,477 $7.54 34
2016 Q1 5,260,385 $45,240,000 +$313,024 $8.60 17
2015 Q4 5,216,906 $47,654,000 +$47,654,000 $9.25 11